added 2007 Fri Mar 9 17:18:22 by SusanParrish
The U.S. biotech industry doesn't face generic competition partly because the Food and Drug Administration lacks authority to approve biotech generics, as it does for easier-to-copy traditional drugs. Legislation reintroduced last month in Congress seeks to give the FDA that authority.
The U.S. biotech industry doesn't face generic competition partly because the Food and Drug Administration lacks authority to approve biotech generics, as it does for easier-to-copy traditional drugs. Legislation reintroduced last month in Congress seeks to give the FDA that authority.
